
KindlyMD ® Shareholders Approve Proposed Merger with Nakamoto Holdings
In connection with the transaction, the parties will prepare and file an information statement with the Securities and Exchange Commission. The merger is expected to close 20 days after the date that the parties mail the information statement to KindlyMD shareholders.
'This milestone brings us one step closer to unlocking Bitcoin's potential for KindlyMD shareholders,' said David Bailey, Founder and CEO of Nakamoto. 'We are grateful that KindlyMD shares our vision for a future in which Bitcoin is a core part of the corporate balance sheet, and investors across global capital markets have exposure to the world's greatest asset and store of value.'
'We are pleased to achieve this important milestone in the merger process,' said Tim Pickett, CEO of KindlyMD. 'As a combined company, we are excited to leverage Bitcoin's dominance and real-world utility to strengthen our company and drive sustained long-term value for our investors.'
About Nakamoto
Nakamoto is a Bitcoin treasury company building a global portfolio of Bitcoin-native companies. Nakamoto plans to establish the first publicly traded conglomerate of Bitcoin companies by accumulating Bitcoin in its treasury and by leveraging its treasury to acquire and develop an ecosystem of Bitcoin companies across finance, media, advisory and more. The company aims to provide commercial and financial infrastructure for the next generation of capital markets. For more information, please visit nakamoto.com.
About KindlyMD
KindlyMD is a patient-first healthcare and healthcare data company redefining value-based care and patient-centered medical services. KindlyMD leverages data analysis to deliver evidence-based, personalized solutions in order to reduce opioid use, improve health outcomes faster, and provide algorithmic guidance on the use of alternative medicine in healthcare. KindlyMD provides a patient-focused healthcare experience that integrates traditional medical evaluation and management with mental health integration and compliant alternative medicine education and inclusion. It focuses on creating personalized care plans for each individual that get people back to work and life faster, reduce opioid use, and yield high patient satisfaction.
Its specialty outpatient clinical services are reimbursed by Medicare, Medicaid, and commercial insurance contracts as well as offered on a fee-for-service basis. For more information, please visit www.kindlymd.com.
Forward-Looking Statements
All statements, other than statements of historical fact, included in this release that address activities, events or developments that KindlyMD or Nakamoto expects, believes or anticipates will or may occur in the future are forward-looking statements. Words such as 'estimate,' 'project,' 'predict,' 'believe,' 'expect,' 'anticipate,' 'potential,' 'create,' 'intend,' 'could,' 'would,' 'may,' 'plan,' 'will,' 'guidance,' 'look,' 'goal,' 'future,' 'build,' 'focus,' 'continue,' 'strive,' 'allow' or the negative of such terms or other variations thereof and words and terms of similar substance used in connection with any discussion of future plans, actions, or events identify forward-looking statements. However, the absence of these words does not mean that the statements are not forward-looking. These forward-looking statements include, but are not limited to, statements regarding the proposed merger and related transactions, (collectively, the 'Transactions') the expected closing of the proposed Transactions and the timing thereof and as adjusted descriptions of the post-transaction company and its operations, strategies and plans, integration, debt levels and leverage ratio, capital expenditures, cash flows and anticipated uses thereof, synergies, opportunities and anticipated future performance, including the management team and board of directors of the combined company and expected use of proceeds from the Transactions, and any post-closing transactions contemplated between the combined company and BTC Inc (and/or UTXO, LLC through BTC Inc). Information adjusted for the proposed Transactions should not be considered a forecast of future results. There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements included in this release. These include the risk that KindlyMD and Nakamoto businesses (which may include the businesses of BTC Inc and/or UTXO in the future, as applicable) will not be integrated successfully and the risk that KindlyMD or the applicable governing bodies of BTC Inc and/or UTXO may not pursue or approve the terms of an acquisition of BTC Inc and/or UTXO; the risk that cost savings, synergies and growth from the proposed transaction may not be fully realized or may take longer to realize than expected; the possibility that shareholders of KindlyMD may not approve the issuance of new shares of KindlyMD common stock in the Transactions or that shareholders of KindlyMD may not approve the Transactions; the risk that a condition to closing of the Transactions may not be satisfied, that either party may terminate the merger agreement, the subscription agreements of the convertible debt purchase agreement or that the closing of the Transactions might be delayed or not occur at all; potential adverse reactions or changes to business or employee relationships, including those resulting from the announcement or completion of the Transactions; the parties do not receive regulatory approval of the Transactions; the occurrence of any other event, change, or other circumstances that could give rise to the termination of the merger agreement relating to the Transactions; the risk that changes in KindlyMD's capital structure and governance could have adverse effects on the market value of its securities; the ability of KindlyMD and Nakamoto to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers and on KindlyMD and Nakamoto's operating results and business generally; the risk the Transactions could distract management from ongoing business operations or cause KindlyMD and/or Nakamoto to incur substantial costs; the risk that KindlyMD may be unable to reduce expenses or access financing or liquidity; the impact of any related economic downturn; the risk of changes in governmental regulations or enforcement practices; and other important factors that could cause actual results to differ materially from those projected. All such factors are difficult to predict and are beyond KindlyMD's and Nakamoto's control, including those detailed in KindlyMD's Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and such other documents of KindlyMD filed, or to be filed, with the SEC that are or will be available on KindlyMD's website at www.kindlymd.com and on the website of the SEC at www.sec.gov. All forward-looking statements are based on assumptions that KindlyMD and Nakamoto believe to be reasonable but that may not prove to be accurate. Any forward-looking statement speaks only as of the date on which such statement is made, and neither KindlyMD or Nakamoto undertakes any obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Calumet Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Explore Calumet's Fair Values from the Community and select yours Calumet (NASDAQ:CLMT) Second Quarter 2025 Results Key Financial Results Revenue: US$1.03b (down 9.4% from 2Q 2024). Net loss: US$147.9m (loss widened by 271% from 2Q 2024). US$1.70 loss per share (further deteriorated from US$0.49 loss in 2Q 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Calumet Revenues Beat Expectations, EPS Falls Short Revenue exceeded analyst estimates by 8.3%. Earnings per share (EPS) missed analyst estimates significantly. Looking ahead, revenue is forecast to grow 3.9% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Oil and Gas industry in the US. Performance of the American Oil and Gas industry. The company's shares are down 7.4% from a week ago. Risk Analysis We should say that we've discovered 3 warning signs for Calumet (2 don't sit too well with us!) that you should be aware of before investing here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
10 minutes ago
- Yahoo
Hancock Whitney Second Quarter 2025 Earnings: EPS Misses Expectations
Explore Hancock Whitney's Fair Values from the Community and select yours Hancock Whitney (NASDAQ:HWC) Second Quarter 2025 Results Key Financial Results Revenue: US$360.6m (up 3.2% from 2Q 2024). Net income: US$113.0m (flat on 2Q 2024). Profit margin: 31% (down from 33% in 2Q 2024). The decrease in margin was driven by higher expenses. EPS: US$1.32. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. All figures shown in the chart above are for the trailing 12 month (TTM) period Hancock Whitney EPS Misses Expectations Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 2.8%. Looking ahead, revenue is forecast to grow 7.8% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Banks industry in the US. Performance of the American Banks industry. The company's shares are up 1.1% from a week ago. Balance Sheet Analysis While earnings are important, another area to consider is the balance sheet. We have a graphic representation of Hancock Whitney's balance sheet and an in-depth analysis of the company's financial position. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
10 minutes ago
- Yahoo
Why new IPOs are crushing it out of the block
"This company is not aspirational — it's operational." Firefly Aerospace (FLY) CEO Jason Kim said this to me on Yahoo Finance as his company was going through its rite of passage at the Nasdaq on Thursday. It felt so electric in the room, I asked Firefly's employees to clap us in at the top of the interview (video above). The stock opened at $70 a share and closed the session at $60.35 — up 34% from its IPO price of $45. The company's market cap at the end of its first trading day stood at $8.48 billion. Just last week, Firefly said it had planned to sell 16.2 million shares at a range of $35 to $39. A new regulatory filing on Monday came with a much higher range of $41 to $43. The company ended up raising $868 million from the IPO after selling 19.3 million shares at $45. I think Kim's comment perfectly captures why recent IPOs have been embraced enthusiastically by investors. The early-stage companies coming to market are more mature. The businesses are more complete. The leaders are more well-rounded. (Kim told me off camera he is very ready for his first earnings call.) Firefly may still be early stage with no profits, but it's not just hot air with no substance. It's not a SPAC with a suspect leader — hearkening back to the flops from 2020. Kim is an Air Force veteran who spent considerable time working at Boeing's satellite business. His company is part of NASA's Commercial Lunar Payload Services program. Its lunar lander Blue Ghost successfully touched down on the surface of the moon in March. The company's new Eclipse reusable rocket is expected to launch sometime in 2026, joining the already proven Alpha rocket in the portfolio. In its prospectus, Firefly boasted $1.1 billion in backlog and lists partnerships with Elon Musk's SpaceX ( Jeff Bezos's Blue Origin, NASA, Northrop Grumman (NOC), and Space Force. Another recent IPO that is more operational than inspirational? Figma (FIG) shares were priced at $33 for its market debut on July 31 and ended the day at $115.50. The company makes software that allows people to collaborate on slide decks and digital whiteboards, among other bells and whistles. The company has more than 13 million monthly users. Its prospectus calls out that 1,000 clients are paying it north of $100,000 a year to use the product. Key customers include Google (GOOG) and Microsoft (MSFT). Sales are growing in double digits, and the company has an operating profit. Then there's Chime, which priced its IPO at $27 and ended its first trading day on June 12 at $37.11. The company reported better-than-expected earnings this past week, though the stock now trades around $30. CFO Matt Newcomb said the team has had conversations with investors, and they recognize the fintech's business model and progress. "I think as it relates to stock price, not uncommon for new companies to see some volatility out of the gate," he told me on Opening Bid. The same operational, not aspirational vibe could be felt at Circle (CRCL), which kicked off the strong market responses for IPOs earlier this year. CEO Jeremy Allaire is a widely respected blockchain industry veteran. It's good to see the healthy IPO activity, and sources tell me more could be on the way in September. Note that 59 US IPOs cumulatively raised $15.02 billion in the second quarter, up 33.8% sequentially, according to S&P Global Market Intelligence data. "The shadow backlog and pace of new IPOs are building, coupled with investor demand, that sets the stage for a great second half," S&P said. Brian Sozzi is Yahoo Finance's Executive Editor and a member of Yahoo Finance's editorial leadership team. Follow Sozzi on X @BrianSozzi, Instagram, and LinkedIn. Tips on stories? Email Click here for in-depth analysis of the latest stock market news and events moving stock prices Sign in to access your portfolio